HRP20170810T1 - Peptidi i spojevi koji se vežu za receptore trombopoietina - Google Patents

Peptidi i spojevi koji se vežu za receptore trombopoietina Download PDF

Info

Publication number
HRP20170810T1
HRP20170810T1 HRP20170810TT HRP20170810T HRP20170810T1 HR P20170810 T1 HRP20170810 T1 HR P20170810T1 HR P20170810T T HRP20170810T T HR P20170810TT HR P20170810 T HRP20170810 T HR P20170810T HR P20170810 T1 HRP20170810 T1 HR P20170810T1
Authority
HR
Croatia
Prior art keywords
compound
cells
use according
sarcosine
nal
Prior art date
Application number
HRP20170810TT
Other languages
English (en)
Croatian (hr)
Inventor
Brian R. Macdonald
Jeffery Kenneth Weis
Edward John Yurkow
Original Assignee
Janssen Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272720&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20170810(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceuticals, Inc. filed Critical Janssen Pharmaceuticals, Inc.
Publication of HRP20170810T1 publication Critical patent/HRP20170810T1/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/524Thrombopoietin, i.e. C-MPL ligand
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/03Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
HRP20170810TT 2003-08-28 2004-08-13 Peptidi i spojevi koji se vežu za receptore trombopoietina HRP20170810T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49874003P 2003-08-28 2003-08-28
EP04781153.4A EP1675606B1 (en) 2003-08-28 2004-08-13 Peptides and compounds that bind to thrombopoietin receptors
PCT/US2004/026422 WO2005023834A2 (en) 2003-08-28 2004-08-13 Peptides and compounds that bind to thrombopoietin receptors

Publications (1)

Publication Number Publication Date
HRP20170810T1 true HRP20170810T1 (hr) 2017-08-11

Family

ID=34272720

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20170810TT HRP20170810T1 (hr) 2003-08-28 2004-08-13 Peptidi i spojevi koji se vežu za receptore trombopoietina

Country Status (32)

Country Link
US (1) US7576056B2 (https=)
EP (1) EP1675606B1 (https=)
JP (1) JP4848277B2 (https=)
KR (2) KR101183875B1 (https=)
CN (2) CN102241742B (https=)
AR (1) AR045530A1 (https=)
AU (1) AU2004270656B2 (https=)
BR (1) BRPI0414008B8 (https=)
CA (1) CA2537421C (https=)
CY (1) CY1118965T1 (https=)
DK (1) DK1675606T3 (https=)
EA (1) EA009286B1 (https=)
EC (1) ECSP066396A (https=)
ES (1) ES2626107T3 (https=)
HR (1) HRP20170810T1 (https=)
HU (1) HUE032370T2 (https=)
IL (1) IL173965A (https=)
IS (1) IS8300A (https=)
LT (1) LT1675606T (https=)
ME (1) ME00313B (https=)
MX (1) MXPA06002292A (https=)
NO (1) NO344233B1 (https=)
NZ (1) NZ545455A (https=)
PL (1) PL1675606T3 (https=)
PT (1) PT1675606T (https=)
RS (2) RS56387B1 (https=)
SG (1) SG131110A1 (https=)
SI (1) SI1675606T1 (https=)
TW (1) TWI348375B (https=)
UA (1) UA82710C2 (https=)
WO (1) WO2005023834A2 (https=)
ZA (1) ZA200602495B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
PT1783222E (pt) 1998-10-23 2012-07-26 Kirin Amgen Inc Péptidos diméricos de trombopoietina que simulam a ligação ao receptor mpl e têm actividade trombopoiética
KR20050093759A (ko) * 2002-09-18 2005-09-23 오르토-맥네일 파마슈티칼, 인코퍼레이티드 혈소판 및 조혈 줄기세포의 생산을 증가시키는 방법
US20040149235A1 (en) * 2002-10-04 2004-08-05 Pogue Albert S. Apparatus and method for removal of waste from animal production facilities
US7576056B2 (en) 2003-08-28 2009-08-18 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US7723295B2 (en) * 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
US7615533B2 (en) 2004-08-16 2009-11-10 Janssen Pharmaceutica N.V. TPO peptide compounds for treatment of anemia
US20090053242A1 (en) * 2006-01-25 2009-02-26 Amgen Inc. Thrombopoietic compounds
MY151332A (en) * 2006-02-14 2014-05-15 Janssen Pharmaceutica Nv Use of tpo peptide compounds and pharmaceutical compositions in the treatment of anemia
WO2007094781A1 (en) * 2006-02-14 2007-08-23 Janssen Pharmaceutica N.V. Use of tpo peptide compounds and pharmaceutical compositions in the treatment of anemia
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
KR20110015448A (ko) * 2008-06-03 2011-02-15 얀센 파마슈티카 엔.브이. 암 치료와 관련된 혈액 질환을 예방하기 위한 tpo 모방 펩티드
EP2725053B1 (en) 2011-06-23 2016-02-10 Shimadzu Corporation Branched amphipathic block polymer and molecular aggregate and drug delivery system using same
CA3070442A1 (en) * 2017-07-26 2019-01-31 Janssen Pharmaceutica Nv Methods of protecting vascular integrity induced by targeted radiation therapy
CN113905754B (zh) 2019-01-25 2025-03-11 詹森药业有限公司 减轻起疱剂和腐蚀性气体毒性作用的方法
CN113766926A (zh) 2019-01-25 2021-12-07 詹森药业有限公司 与放射和/或放射模拟物治疗结合的减轻肝损伤和促进肝肥大、再生和细胞植入的方法
MX2021008928A (es) * 2019-01-25 2021-11-04 Janssen Pharmaceutica Nv Métodos para mejorar la protección contra lesiones vasculares y de organos, la recuperación hematopoyética y la supervivencia en respuesta a la radiacion corporal total/exposicion química.
WO2023056444A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica N.V. Methods of increasing progenitor cell production
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5326558A (en) 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
IL96477A0 (en) 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
DK167813B1 (da) 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
US5571508A (en) 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
IT1241395B (it) 1990-04-02 1994-01-10 Eniricerche Spa Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria
US5141851A (en) 1990-04-18 1992-08-25 Board Of Regents, The University Of Texas System Isolated farnesyl protein transferase enzyme
US5250732A (en) 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
ES2181691T5 (es) 1992-06-11 2007-10-01 Alkermes Controlled Therapeutics, Inc. Sistema de distribucion de proteina eritropoyetina.
JP3401005B2 (ja) 1992-12-11 2003-04-28 ユニバーシティ オブ フロリダ 有害生物の防除のための材料および方法
AU8124694A (en) 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
SG47030A1 (en) 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
SK100896A3 (en) 1994-02-14 1997-10-08 Zymogenetics Inc Hematopoietic protein and materials and methods for making it
WO1995021626A1 (en) 1994-02-14 1995-08-17 University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
EP0668352A1 (en) 1994-02-14 1995-08-23 Kirin Brewery Company, Ltd. Protein having TPO activity
CN1229385C (zh) 1994-03-31 2005-11-30 安姆根有限公司 刺激巨核细胞生长和分化的组合物及方法
US5571686A (en) 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
WO1996014293A1 (en) * 1994-11-04 1996-05-17 Santen Pharmaceutical Co., Ltd. Novel 1,3-dialkylurea derivative having hydroxyl group
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
AU4163196A (en) 1994-11-30 1996-06-19 Zymogenetics Inc. Low molecular weight thrombopoietin
AU705064B2 (en) 1995-04-26 1999-05-13 Kyowa Hakko Kogyo Co. Ltd. Novel polypeptides
TR199701526T1 (xx) 1995-06-07 1998-03-21 Glaxo Group Limited Bir trombopoietin resept�r�ne ba�lanan peptitler ve bile�ikler.
US6251864B1 (en) * 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6060052A (en) 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
US5932546A (en) 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
ATE350044T1 (de) 1999-09-24 2007-01-15 Smithkline Beecham Corp Thrombopoietinmimetika
HU229701B1 (en) * 2000-12-22 2014-05-28 Ipsen Manufactoring Ireland Ltd Process for the synthesis of a peptide having a trp residue
AU2002307062A1 (en) 2001-04-02 2002-10-15 Purdue Pharma L.P. Thrombopoietin (tpo) synthebody for stimulation of platelet production
KR20050093759A (ko) 2002-09-18 2005-09-23 오르토-맥네일 파마슈티칼, 인코퍼레이티드 혈소판 및 조혈 줄기세포의 생산을 증가시키는 방법
US7576056B2 (en) 2003-08-28 2009-08-18 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor

Also Published As

Publication number Publication date
JP2007504132A (ja) 2007-03-01
AU2004270656A1 (en) 2005-03-17
ECSP066396A (es) 2006-08-30
NO344233B1 (no) 2019-10-14
SG131110A1 (en) 2007-04-26
NZ545455A (en) 2009-02-28
HK1096873A1 (en) 2007-06-15
SI1675606T1 (sl) 2017-07-31
MXPA06002292A (es) 2006-09-04
BRPI0414008A (pt) 2006-10-24
WO2005023834A3 (en) 2005-05-06
KR20070017942A (ko) 2007-02-13
IL173965A0 (en) 2006-07-05
EP1675606B1 (en) 2017-04-05
ZA200602495B (en) 2007-06-27
CA2537421A1 (en) 2005-03-17
CN102241742A (zh) 2011-11-16
ES2626107T3 (es) 2017-07-24
RS56387B1 (sr) 2017-12-29
EP1675606A2 (en) 2006-07-05
IL173965A (en) 2015-10-29
KR101183875B1 (ko) 2012-09-27
EA200600477A1 (ru) 2007-02-27
BRPI0414008B8 (pt) 2021-05-25
AR045530A1 (es) 2005-11-02
NO20061346L (no) 2006-05-22
DK1675606T3 (en) 2017-06-19
EP1675606A4 (en) 2009-09-30
EA009286B1 (ru) 2007-12-28
AU2004270656B2 (en) 2011-03-10
US20050137133A1 (en) 2005-06-23
ME00313B (me) 2011-05-10
CA2537421C (en) 2011-09-27
US7576056B2 (en) 2009-08-18
JP4848277B2 (ja) 2011-12-28
RS20060141A (sr) 2008-08-07
PL1675606T3 (pl) 2017-08-31
CN102241742B (zh) 2014-04-02
TWI348375B (en) 2011-09-11
UA82710C2 (uk) 2008-05-12
MEP48508A (en) 2011-02-10
IS8300A (is) 2006-02-14
HUE032370T2 (en) 2017-09-28
CN1871022B (zh) 2011-07-06
CY1118965T1 (el) 2018-01-10
TW200517103A (en) 2005-06-01
BRPI0414008B1 (pt) 2018-05-15
WO2005023834A2 (en) 2005-03-17
CN1871022A (zh) 2006-11-29
KR20120078742A (ko) 2012-07-10
PT1675606T (pt) 2017-05-22
LT1675606T (lt) 2017-11-10

Similar Documents

Publication Publication Date Title
HRP20170810T1 (hr) Peptidi i spojevi koji se vežu za receptore trombopoietina
EP2726115B1 (en) Procoagulant peptides and their derivatives and uses therefor
Choi et al. Covalently conjugated transforming growth factor-β1 in modular chitosan hydrogels for the effective treatment of articular cartilage defects
ES2703826T3 (es) Inmunoterapia con IL-12 destinada al cáncer
US20060115457A1 (en) Biocompatible hydrogel compositions
US20230226142A1 (en) Ionic self-assembling peptides
BRPI0514297A (pt) composições farmacêuticas para liberação controlada de compostos biologicamente ativos
US10869955B2 (en) Joint fat pad formulations, and methods of use thereof
EP2506852A2 (en) Interferon therapies in combination with blockade of stat3 activation
EP2601241A1 (en) Absorbable peg-based hydrogels
TW201111003A (en) Injectable aqueous ophthalmic composition and method of use therefor
BR0308137A (pt) Formulações de droga de liberação constante contendo um peptìdeo veìculo
US20160022872A1 (en) Cell-based compositions, cell-based bandage devices and systems and methods of treatment therewith
JP2007504132A5 (https=)
EP1455766B1 (en) Thymosin alpha 1 peptide/polymer conjugates
CA2380216C (en) Use of interleukin-18 inhibitors to inhibit tumor metastasis
JP2009504650A5 (https=)
ES2607986T3 (es) Agentes terapéuticos para regular el fósforo en suero
AU2009208481B2 (en) Pharmaceutical composition and combined agent
EA037151B1 (ru) Способ лечения с использованием пегилированного интерферона
WO2005009333A2 (en) Combined treatments comprising synthetic peptide copolymers for preventing graft rejection
NZ532763A (en) Method of administering a thymosin alpha 1 peptide
Ubhe IL-1 receptor antagonist: etiological and drug delivery systems overview
Li et al. Prospective application of stem cells to prevent post‐operative skeletal fibrosis
KR20260001925A (ko) 점착력 및 겔화 속도가 개선된 온도감응성 하이드로겔 조성물